Recombinant human interferon a2b(rhIFNa2b)is widely used as an antiviral therapy agent for the treatment of hepatitis B and hepatitis C.The current identification test for rhIFNa2b is complex.In this study,an anti-rhI...Recombinant human interferon a2b(rhIFNa2b)is widely used as an antiviral therapy agent for the treatment of hepatitis B and hepatitis C.The current identification test for rhIFNa2b is complex.In this study,an anti-rhIFNa2b nanobody was discovered and used for the development of a rapid lateral flow strip for the identification of rhIFNa2b.RhIFNa2b was used to immunize an alpaca,which established a phage nanobody library.After five steps of enrichment,the nanobody I22,which specifically bound rhIFNa2b,was isolated and inserted into the prokaryotic expression vector pET28a.After subsequent purification,the physicochemical properties of the nanobody were determined.A semiquantitative detection and rapid identification assay of rhIFNa2b was developed using this novel nanobody.To develop a rapid test,the nanobody I22 was coupled with a colloidal gold to produce lateral-flow test strips.The developed rhIFNa2b detection assay had a limit of detection of 1 mg/mL.The isolation of I22 and successful construction of a lateral-flow immunochromatographic test strip demonstrated the feasibility of performing ligand-binding assays on a lateral-flow test strip using recombinant protein products.The principle of this novel assay is generally applicable for the rapid testing of other commercial products,with a great potential for routine use in detecting counterfeit recombinant protein products.展开更多
目的研究宫颈高危型HPV感染应用重组人干扰素α2b阴道泡腾胶囊治疗的作用。方法选取100例宫颈高危型HPV感染患者,根据随机数字表法分为研究组与一般组,各50例。一般组定期随访不做任何处理,研究组采用重组人干扰素α2b阴道泡腾胶囊治疗...目的研究宫颈高危型HPV感染应用重组人干扰素α2b阴道泡腾胶囊治疗的作用。方法选取100例宫颈高危型HPV感染患者,根据随机数字表法分为研究组与一般组,各50例。一般组定期随访不做任何处理,研究组采用重组人干扰素α2b阴道泡腾胶囊治疗。比较两组转阴情况、治疗前后生活质量评分。结果研究组转阴率高于(62.00 vs 22.00)%一般组(P<0.05)。治疗后,研究组生活质量评分(75.98±10.52 vs 85.98±11.03)分高于一般组(P<0.05)。结论宫颈高危型HPV感染患者实施重组人干扰素α2b阴道泡腾胶囊治疗,可有效提高转阴率,改善患者生活质量,值得临床推广。展开更多
Treatment of hepatitis C, even when absolutely necessary, is almost impossible when interferon cannot be administered for any reason. We report a 65-year-old patient with chronic hepatitis C virus (HCV) infection and ...Treatment of hepatitis C, even when absolutely necessary, is almost impossible when interferon cannot be administered for any reason. We report a 65-year-old patient with chronic hepatitis C virus (HCV) infection and fibrosis, who was unable to receive interferon because of systemic hypersensitivity. The patient was desensitized successfully through gradual incremental exposure to interferon, and HCV infection was eradicated after a complete course of treatment, with no further allergic reactions. This case report that describes successful eradication of hepatitis C in a patient with advanced liver disease after desensitization to interferon revealed that desensitization may not necessarily damage the therapeutic efficacy of the drug.展开更多
目的:观察杀乳瘤毒Ⅰ号方治疗宫颈高危型人乳头瘤病毒(high risk human papillomavirus,HR-HPV)感染者的临床疗效。方法:采用随机、对照的方法将120例宫颈HPV感染患者分为对照组和治疗组,每组60例,对照组给予重组人干扰素a2b阴道泡腾胶...目的:观察杀乳瘤毒Ⅰ号方治疗宫颈高危型人乳头瘤病毒(high risk human papillomavirus,HR-HPV)感染者的临床疗效。方法:采用随机、对照的方法将120例宫颈HPV感染患者分为对照组和治疗组,每组60例,对照组给予重组人干扰素a2b阴道泡腾胶囊阴道用药;治疗组口服杀乳瘤毒Ⅰ号方治疗,30 d为1个疗程。比较两组患者临床疗效、HPV转阴率、未转阴患者病毒载量差值及治疗前后HR-HPV DNA病毒载量、HPVL1壳蛋白水平、白细胞介素-2(interleukin-2,IL-2)、白细胞介素-10(interleukin-10,IL-10)水平以及CD4+、CD8+T淋巴细胞亚群水平变化情况。结果:治疗组有效率为91.7%,对照组有效率为76.7%,两组比较,差异有统计学意义(P<0.01);治疗组HPV转阴率68.3%,对照组HPV转阴率38.3%,两组比较,差异有统计学意义(P<0.01);两组均能显著降低HR-HPV DNA病毒载量,且治疗组优于对照组(P<0.01);两组HPV未转阴患者治疗前后病毒载量的差值经对数转换后进行比较,治疗组显著优于对照组(P<0.01);两组均能显著提高HPVL1壳蛋白水平(P<0.05),且治疗组明显优于对照组(P<0.01);两组均能显著降低血清IL-10水平,提高血清IL-2水平(P<0.01),且治疗组优于对照组(P<0.01);两组均能提高血清CD4+水平,降低血清CD8+水平(P<0.01),且治疗组显著优于对照组(P<0.01)。结论:杀乳瘤毒Ⅰ号方治疗HPV感染,可通过有效调节炎性细胞因子和免疫细胞因子,减轻炎性反应,调节机体的免疫功能,进而改善患者预后,临床疗效确切。展开更多
基金support was provided by the National Science and Technology Major Project(Grant No.:2015ZX09501008)。
文摘Recombinant human interferon a2b(rhIFNa2b)is widely used as an antiviral therapy agent for the treatment of hepatitis B and hepatitis C.The current identification test for rhIFNa2b is complex.In this study,an anti-rhIFNa2b nanobody was discovered and used for the development of a rapid lateral flow strip for the identification of rhIFNa2b.RhIFNa2b was used to immunize an alpaca,which established a phage nanobody library.After five steps of enrichment,the nanobody I22,which specifically bound rhIFNa2b,was isolated and inserted into the prokaryotic expression vector pET28a.After subsequent purification,the physicochemical properties of the nanobody were determined.A semiquantitative detection and rapid identification assay of rhIFNa2b was developed using this novel nanobody.To develop a rapid test,the nanobody I22 was coupled with a colloidal gold to produce lateral-flow test strips.The developed rhIFNa2b detection assay had a limit of detection of 1 mg/mL.The isolation of I22 and successful construction of a lateral-flow immunochromatographic test strip demonstrated the feasibility of performing ligand-binding assays on a lateral-flow test strip using recombinant protein products.The principle of this novel assay is generally applicable for the rapid testing of other commercial products,with a great potential for routine use in detecting counterfeit recombinant protein products.
文摘目的研究宫颈高危型HPV感染应用重组人干扰素α2b阴道泡腾胶囊治疗的作用。方法选取100例宫颈高危型HPV感染患者,根据随机数字表法分为研究组与一般组,各50例。一般组定期随访不做任何处理,研究组采用重组人干扰素α2b阴道泡腾胶囊治疗。比较两组转阴情况、治疗前后生活质量评分。结果研究组转阴率高于(62.00 vs 22.00)%一般组(P<0.05)。治疗后,研究组生活质量评分(75.98±10.52 vs 85.98±11.03)分高于一般组(P<0.05)。结论宫颈高危型HPV感染患者实施重组人干扰素α2b阴道泡腾胶囊治疗,可有效提高转阴率,改善患者生活质量,值得临床推广。
文摘Treatment of hepatitis C, even when absolutely necessary, is almost impossible when interferon cannot be administered for any reason. We report a 65-year-old patient with chronic hepatitis C virus (HCV) infection and fibrosis, who was unable to receive interferon because of systemic hypersensitivity. The patient was desensitized successfully through gradual incremental exposure to interferon, and HCV infection was eradicated after a complete course of treatment, with no further allergic reactions. This case report that describes successful eradication of hepatitis C in a patient with advanced liver disease after desensitization to interferon revealed that desensitization may not necessarily damage the therapeutic efficacy of the drug.
